Pedro N Aguiar1, Ilka Lopes Santoro1, Hakaru Tadokoro1, Gilberto de Lima Lopes2, Bruno Andraus Filardi1, Pedro Oliveira3, Pedro Castelo-Branco4, Giannis Mountzios5, Ramon Andrade de Mello4,6,7. 1. Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil. 2. Department of Medical Oncology, Johns Hopkins University, Baltimore, MD 21218, USA. 3. Department of Population Studies, Abel Salazar Biomedical Institute, University of Porto, Porto, Portugal. 4. Division of Oncology, Department of Biomedical Sciences & Medicine, University of Algarve, Faro, Portugal. 5. Department of Medical Oncology, University of Athens Medical School, Athens, Greece. 6. Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal. 7. Research Center, Cearense School of Oncology, Instituto do Câncer do Ceará, Fortaleza, CE, Brazil.
Abstract
BACKGROUND: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. METHODS: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. RESULTS: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. CONCLUSIONS: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.
BACKGROUND: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. METHODS: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. RESULTS: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. CONCLUSIONS: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.
Authors: Vassil Dimitrov; Manuella Bouttier; Giselle Boukhaled; Reyhaneh Salehi-Tabar; Radu G Avramescu; Babak Memari; Benedeta Hasaj; Gergely L Lukacs; Connie M Krawczyk; John H White Journal: J Biol Chem Date: 2017-10-23 Impact factor: 5.157
Authors: Ramon Andrade de Mello; Ana Flávia Veloso; Paulo Esrom Catarina; Sara Nadine; Georgios Antoniou Journal: Onco Targets Ther Date: 2016-12-16 Impact factor: 4.147
Authors: Giuseppe Troiano; Vito C A Caponio; Khrystyna Zhurakivska; Claudia Arena; Giuseppe Pannone; Marco Mascitti; Andrea Santarelli; Lorenzo Lo Muzio Journal: Cell Prolif Date: 2018-11-15 Impact factor: 6.831